{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:42:09Z","timestamp":1784580129185,"version":"3.55.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.critrevonc.2024.104454","type":"journal-article","created":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T14:32:56Z","timestamp":1721572376000},"page":"104454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?"],"prefix":"10.1016","volume":"202","author":[{"given":"Carlos","family":"Ayala-de Miguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-1412","authenticated-orcid":false,"given":"Jer\u00f3nimo","family":"Jim\u00e9nez-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"S\u00e1nchez-Vegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"D\u00edaz-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Chaves-Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clcc.2020.04.003","article-title":"Current Options for Third-Line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion","volume":"19","author":"Fern\u00e1ndez-Montes","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ijc.34558","article-title":"Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis","volume":"153","author":"Kim","year":"2023","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104454_bib3","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2147\/OTT.S192923","article-title":"Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer","volume":"12","author":"Liu","year":"2019","journal-title":"Oncol. Targets Ther."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104454_bib4","doi-asserted-by":"crossref","first-page":"24424","DOI":"10.18632\/aging.202300","article-title":"FOXM1\/DVL2\/Snail axis drives metastasis and chemoresistance of colorectal cancer","volume":"12","author":"Yang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"S2","key":"10.1016\/j.critrevonc.2024.104454_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ajco.13114","article-title":"Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer","volume":"15","author":"Chiang","year":"2019","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.21037\/jgo.2018.04.08","article-title":"Chemotherapy re-challenge response rate in metastatic colorectal cancer","volume":"9","author":"Chambers","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12032-008-9077-8","article-title":"Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: A retrospective analysis","volume":"26","author":"Kang","year":"2009","journal-title":"Med Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104454_bib8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104454_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","article-title":"Therapeutic Landscape and Future Direction of Metastatic Colorectal Cancer","volume":"20","author":"Bando","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3892\/or.2014.3487","article-title":"Repeated Oral Dosing of TAS-102 Confers High Trifluridine Incorporation into DNA and Sustained Antitumor Activity in Mouse Models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol. Rep."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104454_bib11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104454_bib12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (C-TASK FORCE): An Investigator-Initiated, Open-Label, Single-Arm, Multicentre, Phase 1\/2 Study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without Bevacizumab in Patients with Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104454_bib14","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104454_bib15","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2217\/fon-2020-1238","article-title":"Trifluridine\/Tipiracil plus Bevacizumab for Third-Line Management of Metastatic Colorectal Cancer: SUNLIGHT Study Design","volume":"17","author":"Tabernero","year":"2021","journal-title":"Futur. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104454_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17588359221146137","article-title":"Trifluridine\/Tipiracil with or without Bevacizumab in Metastatic Colorectal Cancer: Results of a Systematic Review and Meta-Analysis","volume":"15","author":"Yoshino","year":"2023","journal-title":"Ther. Adv. Med Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib17","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.3390\/curroncol30060397","article-title":"A Systematic Review and Meta-Analysis of Trifluridine\/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series","volume":"30","author":"Voutsadakis","year":"2023","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101614","article-title":"Real-World Evidence of Trifluridine\/Tipiracil plus Bevacizumab in Metastatic Colorectal Cancer Using an Administrative Claims Database in Japan","volume":"8","author":"Kagawa","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clcc.2022.11.005","article-title":"An Exploration of Trifluridine\/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study","volume":"22","author":"Nie","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00280-018-3686-5","article-title":"Safety of Trifluridine\/Tipiracil in an Open-Label Expanded-Access Program in Elderly and Younger Patients with Metastatic Colorectal Cancer","volume":"82","author":"Mayer","year":"2018","journal-title":"Cancer Chemother. Pharm."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104454_bib21","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1634\/theoncologist.2017-0573","article-title":"Trifluridine\/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program","volume":"23","author":"Cremolini","year":"2018","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104454_bib22","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.3390\/cancers13184514","article-title":"Early Clinical Experience with Trifluridine\/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study","volume":"13","author":"Garc\u00eda-Alfonso","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000752","article-title":"Effect of Trifluridine\/Tipiracil in Patients Treated in RECOURSE by Prognostic Factors at Baseline: An Exploratory Analysis","volume":"5","author":"Tabernero","year":"2020","journal-title":"ESMO Open"},{"issue":"9863","key":"10.1016\/j.critrevonc.2024.104454_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"D. Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus Best Supportive Care versus Placebo plus Best Supportive Care in Asian Patients with Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104454_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.011","article-title":"Efficacy and Safety of Regorafenib in the Treatment of Metastatic Colorectal Cancer: A Systematic Review","volume":"62","author":"R\u00f8ed Sk\u00e5rderud","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2024.104454_bib27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","article-title":"Survival, Safety, and Prognostic Factors for Outcome with Regorafenib in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: Results from a Multicenter Study (REBACCA) Nested within a Compassionate Use Program","volume":"16","author":"Adenis","year":"2016","journal-title":"BMC Cancer"},{"issue":"10395","key":"10.1016\/j.critrevonc.2024.104454_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus Placebo in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2): An International, Multicentre, Randomised, Double-Blind, Phase 3 Study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib29","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.3390\/curroncol30060413","article-title":"Treatment Settings and Outcomes with Regorafenib and Trifluridine\/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study","volume":"30","author":"Signorelli","year":"2023","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104454_bib30","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1634\/theoncologist.2019-0189","article-title":"A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer","volume":"24","author":"Sonbol","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104454_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clcc.2017.10.016","article-title":"A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis","volume":"17","author":"Abrahao","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104454_bib32","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s00432-020-03315-6","article-title":"Systematic Review and Network Meta-Analyses of Third-Line Treatments for Metastatic Colorectal Cancer","volume":"146","author":"Walter","year":"2020","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104454_bib33","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.12659\/MSM.918411","article-title":"Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials","volume":"25","author":"Chen","year":"2019","journal-title":"Med Sci. Monit."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.clcc.2021.06.002","article-title":"Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (MCRC) Patients: A Multi-Institution Real Life Clinical Data","volume":"20","author":"Vitale","year":"2021","journal-title":"Clin. Colorectal Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104454_bib35","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104454_bib36","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the Treatment of Colorectal Cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"7404","key":"10.1016\/j.critrevonc.2024.104454_bib37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS Mutations and Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104454_bib38","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","article-title":"Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer","volume":"21","author":"Arena","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib39","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating Tumor DNA to Guide Rechallenge with Panitumumab in Metastatic Colorectal Cancer: The Phase 2 CHRONOS Trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104454_bib40","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/s41416-020-01042-w","article-title":"Phase 2 Study of Irinotecan plus Cetuximab Rechallenge as Third-Line Treatment in KRAS Wild-Type Metastatic Colorectal Cancer: JACCRO CC-08","volume":"123","author":"Masuishi","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s11523-021-00845-y","article-title":"Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09","volume":"16","author":"Tsuji","year":"2021","journal-title":"Target Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer with Acquired Resistance to First-Line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2024.104454_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940523","article-title":"CAVE-2 (Cetuximab-AVElumab) MCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS\/BRAF Wild-Type MCRC Patients","volume":"12","author":"Napolitano","year":"2022","journal-title":"Front Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104454_bib44","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib45","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1002\/cam4.5699","volume":"12","author":"Martini","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2024.104454_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2018.12.006","article-title":"Retreatment with Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer: Systematic Review of Different Strategies","volume":"73","author":"Mauri","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104454_bib49","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized Phase III Study of Capecitabine plus Oxaliplatin Compared With Fluorouracil\/Folinic Acid Plus Oxaliplatin As First-Line Therapy For Metastatic Colorectal Cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib50","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","article-title":"RL. Oral Capecitabine vs Intravenous 5-Fluorouracil and Leucovorin: Integrated Efficacy Data and Novel Analyses from Two Large, Randomised, Phase III Trials","volume":"90","author":"Cutsem","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104454_bib51","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"9209","key":"10.1016\/j.critrevonc.2024.104454_bib52","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan Combined with Fluorouracil Compared with Fluorouracil Alone as First-Line Treatment for Metastatic Colorectal Cancer: A Multicentre Randomised Trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer - A GERCOR Study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104454_bib54","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2147\/DDDT.S85567","article-title":"Phase II Study of Reintroduction of Oxaliplatin for Advanced Colorectal Cancer in Patients Previously Treated with Oxaliplatin and Irinotecan: RE-OPEN Study","volume":"9","author":"Suenaga","year":"2015","journal-title":"Drug Des. Devel Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000087285","article-title":"Continuous Infusion of Oxaliplatin plus Chronomodulated Capecitabine in 5-Fluorouracil- and Irinotecan-Resistant Advanced Colorectal Cancer Patients","volume":"69","author":"Santini","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2024.104454_bib56","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/OTT.S154220","article-title":"Rechallenge of Oxaliplatin-Containing Regimens in the Third- or Later-Line Therapy for Patients with Heavily Treated Metastatic Colorectal Cancer","volume":"11","author":"Yang","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clcc.2017.03.002","article-title":"REOX: Evaluation of the Efficacy of Re-Treatment with Oxaliplatin-Containing Regimen in Metastatic Colorectal Cancer. A Retrospective Single-Center Study","volume":"16","author":"Costa","year":"2017","journal-title":"Clin. Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COC.0b013e31823fe40e","article-title":"Rechallenge With Oxaliplatin and Fluoropyrimidine for Metastatic Colorectal Carcinoma After Prior Therapy","volume":"36","author":"Townsend","year":"2013","journal-title":"Am. J. Clin. Oncol. Cancer Clin. Trials"},{"key":"10.1016\/j.critrevonc.2024.104454_bib59","doi-asserted-by":"crossref","unstructured":"Larsen F.O., Boisen M.K., Fromm A.L., Jensen B.V. Capecitabine and Bevacizumab in Heavily Pre- Treated Patients with Advanced Colorectal Cancer Capecitabine and Bevacizumab in Heavily Pre-Treated Patients. Acta Oncol. 2012, 51(2): 231\u2013233. \u3008https:\/\/doi.org\/10.3109\/0284186X.2011.614637.\u3009.","DOI":"10.3109\/0284186X.2011.614637"},{"key":"10.1016\/j.critrevonc.2024.104454_bib60","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2147\/OTT.S88679","article-title":"Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer","volume":"8","author":"Yang","year":"2015","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2024.104454_bib61","first-page":"53","article-title":"Bevacizumab plus Chemotherapy as Salvage Treatment in Chemorefractory Patients with Metastatic Colorectal Cancer","volume":"6","author":"Geva","year":"2013","journal-title":"Onco Targets Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab Deruxtecan (DS-8201) in Patients with HER2-Expressing Metastatic Colorectal Cancer (DESTINY-CRC01): A Multicentre, Open-Label, Phase 2 Trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib63","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-Targeted Therapy with Trastuzumab and Lapatinib in Treatment-Refractory, KRAS Codon 12\/13 Wild-Type, HER2-Positive Metastatic Colorectal Cancer (HERACLES): A Proof-of-Concept, Multicentre, Open-Label, Phase 2 Trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104454_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and Trastuzumab Emtansine in Patients with HER2-Amplified Metastatic Colorectal Cancer: The Phase II HERACLES-B Trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus Trastuzumab for HER2-Amplified Metastatic Colorectal Cancer (MyPathway): An Updated Report from a Multicentre, Open-Label, Phase 2a, Multiple Basket Study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104454_bib66","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"MOUNTAINEER investigators. Tucatinib plus Trastuzumab for Chemotherapy-Refractory, HER2-Positive, RAS Wild-Type Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER): A Multicentre, Open-Label, Phase 2 Study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib67","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00306","article-title":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2\/3 Mutations: Results From the TAPUR Study","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib68","first-page":"83","article-title":"Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer","volume":"7","author":"Rawla","year":"2019","journal-title":"Med Sci."},{"issue":"26","key":"10.1016\/j.critrevonc.2024.104454_bib69","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104454_bib70","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104454_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib72","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit with Nivolumab plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2024.104454_bib73","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2016.34.15_suppl.3501","article-title":"Nivolumab \u00b1 Ipilimumab in Treatment (Tx) of Patients (Pts) with Metastatic Colorectal Cancer (MCRC) with and without High Microsatellite Instability (MSI-H): CheckMate-142 Interim Results","volume":"34","author":"Overman","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib74","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104454_bib75","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic Colorectal Cancer (KEYNOTE-177): Final Analysis of a Randomised, Open-Label, Phase 3 Study","volume":"23","author":"Diaz LA","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104454_bib76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"A. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3_suppl.","key":"10.1016\/j.critrevonc.2024.104454_bib77","doi-asserted-by":"crossref","first-page":"LBA768","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA768","article-title":"Nivolumab (NIVO) plus Ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study","volume":"42","author":"Andre","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13073-023-01234-y","article-title":"Recommendations for the Classification of Germline Variants in the Exonuclease Domain of POLE and POLD1","volume":"15","author":"Mur","year":"2023","journal-title":"Genome Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104454_bib79","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1038\/s41436-020-0922-2","article-title":"Role of POLE and POLD1 in Familial Cancer","volume":"22","author":"Mur","year":"2020","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib80","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/his.13984","article-title":"Morphological, Immunophenotypical and Molecular Features of Hypermutation in Colorectal Carcinomas with Mutations in DNA Polymerase \u03b5 (POLE)","volume":"76","author":"Forg\u00f3","year":"2020","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib81","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","article-title":"Somatic POLE Proofreading Domain Mutation, Immune Response, and Prognosis in Colorectal Cancer: A Retrospective, Pooled Biomarker Study","volume":"1","author":"Domingo","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104454_bib82","article-title":"Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006658","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Gastrointestinal Cancer","volume":"11","author":"Kelly","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib84","first-page":"660","article-title":"BRAF Mutant Colorectal Cancer as a Distinct Subset of Colorectal Cancer: Clinical Characteristics, Clinical Behavior, and Response to Targeted Therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104454_bib85","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104454_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103646","article-title":"Systematic Review of Randomised Clinical Trials and Observational Studies for Patients with RAS Wild-Type or BRAFV600E-Mutant Metastatic and\/or Unresectable Colorectal Cancer","volume":"173","author":"Garc\u00eda-Alfonso","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib87","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib88","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41598-023-31055-3","article-title":"Systematic Review of NTRK 1\/2\/3 Fusion Prevalence Pan-Cancer and across Solid Tumours","volume":"13","author":"O\u2019Haire","year":"2023","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib89","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104454_bib90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"George D. Entrectinib in Patients with Advanced or Metastatic NTRK Fusion- Positive Solid Tumours: Integrated Analysis of Three Phase 1\u20132 Trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib91","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00245","article-title":"Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers","author":"Salem","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104454_bib92","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/onco.13870","article-title":"The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study","volume":"26","author":"Chida","year":"2021","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104454_bib93","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib94","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104454_bib95","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-Agnostic Efficacy and Safety of Selpercatinib in Patients with RET Fusion-Positive Solid Tumours Other than Lung or Thyroid Tumours (LIBRETTO-001): A Phase 1 \/ 2, Open-Label, Basket Trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104454_bib96","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","article-title":"Peritoneal Carcinomatosis from Colorectal Cancer","volume":"89","author":"Jayne","year":"2002","journal-title":"Br. J. Surg."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104454_bib97","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised Intraperitoneal Aerosol Chemotherapy: Rationale, Evidence, and Potential Indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104454_bib98","doi-asserted-by":"crossref","first-page":"20200109","DOI":"10.1515\/pp-2020-0109","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)-Directed Treatment of Peritoneal Metastasis in End-Stage Colo-Rectal Cancer Patients","volume":"5","author":"Elleb\u00e6k","year":"2020","journal-title":"Pleura Perito"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104454_bib99","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1245\/s10434-020-09558-4","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC)","volume":"28","author":"Rovers","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104454_bib100","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1245\/s10434-020-09508-0","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy for Colorectal Peritoneal Metastases","volume":"28","author":"Tabchouri","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/pp-2023-0038","article-title":"What Is Long-Term Survival in Patients with Peritoneal Metastasis from Gastric, Pancreatic, or Colorectal Cancer? A Study of Patients Treated with Systemic Chemotherapy and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)","volume":"8","author":"Kryh-Jensen","year":"2023","journal-title":"Pleura Perito"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib102","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1245\/s10434-022-11577-2","article-title":"Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study","volume":"29","author":"Taibi","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104454_bib103","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1245\/s10434-022-13010-0","article-title":"Treatment of Peritoneal Metastasis with Pressurized Intraperitoneal Aerosol Chemotherapy: Results from the Prospective PIPAC-OPC2 Study","volume":"30","author":"Graversen","year":"2023","journal-title":"Ann. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104454_bib104","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","article-title":"Quality of Life of Patients with End-Stage Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)","volume":"41","author":"Odendahl","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104454_bib105","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1007\/s00464-021-08802-6","article-title":"Patient-Reported Outcomes during Repetitive Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy for Isolated Unresectable Colorectal Peritoneal Metastases in a Multicenter, Single-Arm, Phase 2 Trial (CRC-PIPAC)","volume":"36","author":"Lurvink","year":"2022","journal-title":"Surg. Endosc."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0300891619868013","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Patients with Peritoneal Metastasized Colorectal, Appendiceal and Small Bowel Cancer","volume":"106","author":"Gockel","year":"2020","journal-title":"Tumori"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104454_bib107","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.3390\/cancers14174275","article-title":"Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin","volume":"14","author":"Adamina","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2024.104454_bib108","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/jgo-20-257","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review","volume":"12","author":"Lurvink","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104454_bib109","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s00432-019-02970-8","article-title":"Hepatic Arterial Chemotherapy with Raltitrexed and Oxaliplatin versus Standard Chemotherapy in Unresectable Liver Metastases from Colorectal Cancer after Conventional Chemotherapy Failure (HEARTO): A Randomized Phase-II Study","volume":"145","author":"Ghiringhelli","year":"2019","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104454_bib110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1245\/s10434-007-9581-7","article-title":"Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure","volume":"15","author":"Boige","year":"2008","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104454_bib111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12029-016-9915-4","article-title":"Outcomes of a Phase I\/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure","volume":"49","author":"Sato","year":"2018","journal-title":"J. Gastrointest. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib112","first-page":"1387","article-title":"Intra-Arterial Infusion of Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) versus Intravenous Therapy (FOLFIRI) for Hepatic Metastases from Colorectal Cancer: Final Results of a Phase III Study","volume":"32","author":"Fiorentini","year":"2012","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib113","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jvir.2013.05.055","article-title":"Transarterial Chemoembolization with Irinotecan Beads in the Treatment of Colorectal Liver Metastases: Systematic Review","volume":"24","author":"Richardson","year":"2013","journal-title":"J. Vasc. Inter. Radio."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104454_bib114","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/cncr.29534","article-title":"Randomized Controlled Trial of Irinotecan Drug-Eluting Beads with Simultaneous FOLFOX and Bevacizumab for Patients with Unresectable Colorectal Liver-Limited Metastasis","volume":"121","author":"Martin","year":"2015","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104454_bib115","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or with Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib116","doi-asserted-by":"crossref","first-page":"614","DOI":"10.21037\/jgo.2017.03.10","article-title":"Updated Survival Outcomes and Analysis of Long-Term Survivors from the MORE Study on Safety and Efficacy of Radioembolization in Patients with Unresectable Colorectal Cancer Liver Metastases","volume":"8","author":"Kennedy","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104454_bib117","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.3390\/curroncol29050277","article-title":"Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database","volume":"29","author":"Nakamura","year":"2022","journal-title":"Curr. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104454_bib118","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/annonc\/mdw191","article-title":"Challenging chemoresistant metastatic colorectal cancer: Therapeutic strategies from the clinic and from the laboratory","volume":"27","author":"Sartore-Bianchi","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib119","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438466","article-title":"State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation","volume":"44","author":"Pathak","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2024.104454_bib120","first-page":"JCO2302736","article-title":"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study","volume":"4","author":"Kawazoe","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib121","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/codi.13130","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy with Oxaliplatin in Colorectal Peritoneal Metastasis","volume":"18","author":"Demtr\u00f6der","year":"2016","journal-title":"Colorectal Dis."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib122","doi-asserted-by":"crossref","DOI":"10.1097\/AS9.0000000000000203","article-title":"Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Origin","volume":"3","author":"H\u00fcbner","year":"2022","journal-title":"Ann. Surg. Open"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104454_bib123","doi-asserted-by":"crossref","first-page":"7814","DOI":"10.1245\/s10434-023-13941-2","article-title":"Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA","volume":"30","author":"Raoof","year":"2023","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104454_bib124","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/pp-2023-0008","article-title":"UK Trial of Pressurised Intraperitoneal Aerosolised Chemotherapy (PIPAC) with Oxaliplatin for Colorectal Cancer Peritoneal Metastases (NCT03868228)","volume":"8","author":"Kyle","year":"2023","journal-title":"Pleura Perito"},{"key":"10.1016\/j.critrevonc.2024.104454_bib125","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Las Cifras Del C\u00e1ncer En Espa\u00f1a 2024; Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM): Madrid, 2024."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104454_bib126","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104454_bib127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.annonc.2023.10.129","article-title":"ESMO Guidelines Committee. Updated Treatment Recommendation for Third-Line Treatment in Advanced Colorectal Cancer from the ESMO Metastatic Colorectal Cancer Living Guideline","volume":"35","author":"Cervantes","year":"2024","journal-title":"Ann. Oncol."},{"issue":"43","key":"10.1016\/j.critrevonc.2024.104454_bib128","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_389574","article-title":"Update on Emerging Therapies for Advanced Colorectal Cancer","author":"Alese","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T14:34:17Z","timestamp":1732458857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":128,"alternative-id":["S1040842824001975"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104454","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104454"}}